Approved
consistent with clarification in FDA memo of 8-13-02. Before its
next submission, FDA shall review the information collection
requirements in this regulation to evaluate whether their utility
justifies their burden. FDA will report on this in its next
submission.
Inventory as of this Action
Requested
Previously Approved
09/30/2005
09/30/2005
08/31/2002
4,184
0
4,184
848,625
0
848,625
0
0
0
Section 501(a)(2)(B) (21 U.S.C.
351(a)(2)(B)) of the Food, Drug, and Cosmetic Act deems a drug to
be adulterated if the methods used in, or facilities or controls
used for, its manufacturer, processing, packing, or holding do not
conform to or are not operated or administered in conformity with
CGMPs to ensure that such drug meets the requirements of the act as
to safety and has the identity and strength, and meets the quality
and purity characteristics, which it purports or is represented to
possess.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.